None of These Medications Are Established Causes of Kidney Stones
Among Wellbutrin (bupropion), lamotrigine, citalopram, and clonidine, none are recognized as significant contributors to kidney stone formation based on current evidence. The provided FDA drug label for Wellbutrin makes no mention of kidney stones as an adverse effect 1, and the available guidelines and research on drug-induced kidney stones do not identify any of these four medications as culprits.
Understanding Drug-Induced Kidney Stones
Drug-induced kidney stones represent only 1-2% of all renal calculi 2. The medications that do cause stones fall into two main categories:
Direct Stone Formation (Poorly Soluble Drugs)
These drugs crystallize directly in urine due to high urinary excretion and poor solubility:
- Protease inhibitors (especially atazanavir) - most common cause 2
- Sulfodiazine - used for cerebral toxoplasmosis
- Ceftriaxone - with high doses or prolonged use
- Ephedrine-containing preparations
Metabolically-Induced Stones
These drugs alter urinary chemistry to promote stone formation:
- Carbonic anhydrase inhibitors (acetazolamide, topiramate) - alter urinary pH and increase stone risk significantly 3, 2, 4
- Uncontrolled calcium/vitamin D supplements 2
Recent Pharmacovigilance Data
Large-scale analysis of the FDA Adverse Event Reporting System identified the drugs most commonly associated with kidney stones 5, 6:
Top reported drugs by frequency:
- Atazanavir (ROR 46.35)
- Topiramate/Topamax (ROR 19.44)
- Lansoprazole/Prevacid (ROR 12.67)
- Proton pump inhibitors
- Antiretroviral drugs
- Certain biologics (adalimumab, infliximab)
Notably absent from these analyses: Wellbutrin (bupropion), lamotrigine, citalopram, and clonidine were not identified among the drugs with significant kidney stone risk signals 5, 6.
Clinical Implications
If a patient on any of these four medications develops kidney stones, the stone formation should be attributed to:
- Metabolic factors (hypercalciuria, hyperoxaluria, hypocitraturia)
- Dietary factors (high sodium, low fluid intake, high animal protein)
- Other medications they may be taking
- Underlying conditions (obesity, metabolic syndrome)
Rather than discontinuing these psychiatric/neurologic medications, focus should be on standard stone prevention strategies: maintaining urine volume >2.5 L/day, dietary modifications based on 24-hour urine analysis, and addressing specific metabolic abnormalities 7, 8, 9.
Important Caveat
While topiramate (an antiepileptic like lamotrigine) is a well-established cause of kidney stones due to its carbonic anhydrase inhibitor properties 3, 2, lamotrigine does not share this mechanism and is not associated with stone formation. This distinction is critical—do not confuse different antiepileptic drugs as having the same adverse effect profile.